CVS Health Restores Zepbound Coverage After Landmark Pricing Deal

Major Shift in Weight-Loss Drug Coverage

CVS Health announced Thursday it will restore coverage for Eli Lilly’s weight-loss drug Zepbound on select formularies. The pharmacy giant will add the treatment as a co-preferred option alongside rival Novo Nordisk’s Wegovy. This marks a significant reversal from last year’s exclusive agreement. The decision aims to give employers and health plans better access to GLP-1 weight-loss treatments. Additionally, CVS plans to offer more affordable options for patients seeking obesity care.

Zepbound will return to CVS Caremark’s commercial formularies on October 1. Caremark, the pharmacy benefit management unit of CVS, had dropped the drug on July 1 last year. CVS secured more favorable pricing from the Danish drugmaker through negotiations. This deal initially made Wegovy the sole preferred obesity treatment on standard plans.

The expanded coverage may benefit up to 30 million Americans on standard commercial plans. Plan sponsors adopting Caremark’s standard formulary template gain new flexibility. However, these sponsors can still opt out of covering GLP-1 drugs for weight loss. Coverage of both Lilly’s and Novo’s treatments isn’t guaranteed for all patients.

New Obesity Pill Joins Coverage Options

CVS will also remove a new-to-market block on Lilly’s recently launched oral pill, Foundayo. The change becomes effective June 1 for plans that approve the drug. A new-to-market block restricts coverage on newly FDA-approved medications. Insurers and pharmacy benefit managers use this policy to evaluate new drugs before adding coverage.

The oral pill represents a significant advance in obesity treatment. This allows patients to choose between injections and pills for weight management. Lilly confirmed that Foundayo will now be covered by all three major pharmacy benefit managers. The drugmaker celebrated the expanded access in a statement Thursday.

“With this expanded coverage, millions of Americans will have access to Zepbound and Foundayo,” Lilly stated. The company emphasized giving patients and doctors real choice in obesity treatment. Lilly pledged to continue working toward universal access. The pharmaceutical giant aims to make these medications available to everyone who needs them.

Competition Drives Down GLP-1 Costs

CVS expects the dual-preferred strategy to drive 10% to 15% additional savings across the weight management category. The healthcare giant touted last year’s exclusive Novo Nordisk agreement as groundbreaking. CVS became the first major pharmacy benefit manager to spur competition in the GLP-1 market. The move successfully helped “bend the cost curve” for expensive obesity medications.

Both Lilly and Novo responded by partnering with CVS on pricing. The healthcare company pointed to successful continued pricing negotiations with both drugmakers. These discussions made the dual-coverage model financially viable for insurers and employers. The competitive pressure motivated both manufacturers to reduce prices significantly.

According to Ed DeVaney, CVS Caremark’s president, the company took a proactive approach to negotiations. This strategy improved affordability and access for customers and their members. The pharmacy benefit manager leveraged its massive purchasing power effectively. Caremark serves as one of the nation’s largest pharmacy benefit managers.

Industry Faces Growing GLP-1 Cost Pressures

The increasing popularity and high prices of GLP-1 drugs have created challenges for employers. Some health plans have limited or dropped coverage for weight-loss use entirely. CVS previously acknowledged that many clients discontinued coverage of GLP-1 drugs for obesity. The financial burden of these medications strained insurance budgets across the industry.

The pharmacy benefit manager system plays a crucial role in drug pricing, negotiating rebates and fees with manufacturers. Additionally, they reimburse pharmacies for patients’ prescriptions. These organizations create formularies listing medications covered by insurance plans. The system determines which drugs patients can access at affordable copayments.

Pharmacy benefit managers negotiate rebates and fees directly with drug manufacturers. They maintain significant influence over which medications gain widespread coverage. Their decisions affect millions of patients’ treatment options nationwide. The organizations serve as crucial intermediaries between drugmakers, insurers, and patients.

Novo Nordisk Maintains Competitive Position

Novo Nordisk expressed satisfaction with the new arrangement in a statement. The company noted that Wegovy injection and newly launched pill retain preferred status on CVS formularies. Caremark patients can remain on those drugs without interruption. The Danish pharmaceutical company maintains strong market position despite sharing preferred status.

The dual-preferred model puts both companies on equal footing in major drug plans. This arrangement benefits Lilly’s efforts to maintain dominance in the blockbuster weight-loss market. Previously, patients on standard plans faced higher out-of-pocket costs for Zepbound. Some needed to navigate additional hurdles to obtain Lilly’s drug instead of Wegovy.

Model May Reshape Specialty Drug Coverage

The competitive model may become an industry standard for managing expensive specialty medications. This approach, which balances manufacturer competition with patient access needs, could reshape drug coverage. Other insurers might adopt similar dual-preferred strategies for different drug categories. The success of CVS’s approach could influence broader pharmacy benefit management practices.

The GLP-1 market continues expanding rapidly as demand for obesity treatments grows. Both Lilly and Novo Nordisk have invested heavily in manufacturing capacity. The companies race to meet surging patient demand for weight-loss medications. Supply constraints have periodically limited access to these blockbuster drugs.

The restored coverage marks a significant victory for Eli Lilly and patients seeking treatment options. The pharmaceutical company regains access to millions of potential customers through Caremark formularies. Patient choice increases substantially with both major GLP-1 treatments covered equally. Doctors can now prescribe based on clinical factors rather than insurance restrictions.